Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.

[1]  G. Forni,et al.  Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding αv β3 integrins. , 2013, Contrast media & molecular imaging.

[2]  J. Buolamwini,et al.  Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer , 2013, Cancer Prevention Research.

[3]  T. Pourmotabbed,et al.  Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer , 2013, Breast Cancer Research.

[4]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[5]  A. Giordano,et al.  Critical choices for modeling breast cancer in transgenic mouse models , 2012, Journal of cellular physiology.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[7]  B. Gusterson,et al.  Human breast development. , 2012, Seminars in cell & developmental biology.

[8]  J. Crown,et al.  Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice , 2012, BMC Cancer.

[9]  M. Wolfert,et al.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.

[10]  A. Borowsky.  Choosing a mouse model: experimental biology in context--the utility and limitations of mouse models of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[11]  P. Kaldis,et al.  Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. , 2011, Neoplasia.

[12]  Yan Liu,et al.  Proteome and transcriptome profiles of a Her2/Neu‐driven mouse model of breast cancer , 2011, Proteomics. Clinical applications.

[13]  Ralph Weissleder,et al.  In vivo imaging in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[14]  B. Nielsen,et al.  Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. , 2010, Cancer research.

[15]  Kazushi Inoue,et al.  MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer , 2009, Expert review of molecular diagnostics.

[16]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[17]  A. Kulkarni,et al.  Generation of Transgenic Mice , 2009, Current protocols in cell biology.

[18]  B. Law,et al.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. , 2008, Neoplasia.

[19]  H. Frierson,et al.  MMTV‐EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone‐responsive tissues , 2008, Journal of cellular biochemistry.

[20]  C. Watson,et al.  Mammary development in the embryo and adult: a journey of morphogenesis and commitment , 2008, Development.

[21]  A. Ashworth,et al.  Pregnancy and the risk of breast cancer. , 2007, Endocrine-related cancer.

[22]  J. Rosen,et al.  Modelling breast cancer: one size does not fit all , 2007, Nature Reviews Cancer.

[23]  C. Bassing,et al.  Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis , 2007, Oncogene.

[24]  D. Nimbalkar,et al.  Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. , 2007, Cancer research.

[25]  Robert D. Cardiff,et al.  Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.

[26]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[27]  Yarong Wang,et al.  Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. , 2007, Cancer research.

[28]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[29]  Gerhard Christofori,et al.  Mouse models of breast cancer metastasis , 2006, Breast Cancer Research.

[30]  I. Holen,et al.  From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies , 2006, Breast Cancer Research and Treatment.

[31]  J. Pipas,et al.  SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation , 2005, Oncogene.

[32]  J. Wysolmerski,et al.  Key stages of mammary gland development: Molecular mechanisms involved in the formation of the embryonic mammary gland , 2005, Breast Cancer Research.

[33]  Goberdhan P Dimri,et al.  Mammary epithelial cell transformation: insights from cell culture and mouse models , 2005, Breast Cancer Research.

[34]  U. Thorgeirsson,et al.  VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms , 2005, Laboratory Investigation.

[35]  Jose Russo,et al.  The protective role of pregnancy in breast cancer , 2005, Breast Cancer Research.

[36]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[37]  Robert B Boxer,et al.  Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. , 2004, Cancer cell.

[38]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[39]  Jose Russo,et al.  Development of the human breast. , 2004, Maturitas.

[40]  S. Hilsenbeck,et al.  Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. , 2004, Journal of the National Cancer Institute.

[41]  M. D’Onofrio,et al.  In vivo mapping of spontaneous mammary tumors in transgenic mice using MRI and ultrasonography , 2004, Journal of magnetic resonance imaging : JMRI.

[42]  I. Russo,et al.  The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[43]  N. Pryer,et al.  Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. , 2003, Molecular cancer therapeutics.

[44]  A. Borowsky.  Genetically engineering a mouse. , 2003, Comparative medicine.

[45]  R. Cardiff.  Mouse models of human breast cancer. , 2003, Comparative medicine.

[46]  Jeffrey Wyckoff,et al.  GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. , 2002, Cancer research.

[47]  S. Dilworth.  Polyoma virus middle T antigen and its role in identifying cancer-related molecules , 2002, Nature Reviews Cancer.

[48]  Mitchell D Schnall,et al.  Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.

[49]  C. Hudis,et al.  Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. , 2002, Cancer research.

[50]  M. Hofker,et al.  Transgenic Mouse Methods and Protocols , 2002, Methods in Molecular Biology.

[51]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[52]  C. Deng,et al.  Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer , 2002, Oncogene.

[53]  P. Furth,et al.  Loss of Stat5a delays mammary cancer progression in a mouse model , 2002, Oncogene.

[54]  D. J. Jerry,et al.  Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer? , 2002, Breast Cancer Research.

[55]  N. Kenney,et al.  Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E , 2002, Oncogene.

[56]  L. Hennighausen,et al.  Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice , 2001, Transgenic Research.

[57]  R. Cardiff,et al.  In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53 , 2001, Transgenic Research.

[58]  M. Lewandoski.  Conditional control of gene expression in the mouse , 2001, Nature Reviews Genetics.

[59]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[60]  J. Price,et al.  DNA vaccination against neu reduces breast cancer incidence and metastasis in mice , 2001, Cancer Gene Therapy.

[61]  D. Malkin.  Li-fraumeni syndrome. , 2001, Genes & cancer.

[62]  P. Blackshear.  Genetically Engineered Rodent Models of Mammary Gland Carcinogenesis: An Overview , 2001, Toxicologic pathology.

[63]  K. Korach,et al.  Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. , 2000, Cancer research.

[64]  P. Furth,et al.  Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice , 2000, Oncogene.

[65]  B. Trock,et al.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance , 2000, British Journal of Cancer.

[66]  F. Kittrell,et al.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. , 2000, The American journal of pathology.

[67]  D. Liao,et al.  c-Myc in breast cancer. , 2000, Endocrine-related cancer.

[68]  F. Leenders,et al.  Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation , 2000, Oncogene.

[69]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Cheryl Jorcyk,et al.  The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.

[71]  C. Deng,et al.  Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation , 2000, Oncogene.

[72]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[73]  H. Varmus,et al.  Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer , 2000, Oncogene.

[74]  R. Laucirica,et al.  WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis , 2000, Oncogene.

[75]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[76]  A. Scharl,et al.  H-ras gene amplification or mutation is not common in human primary breast cancer. , 1999, Oncology reports.

[77]  S. Korsmeyer,et al.  Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40‐TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage , 1999, The EMBO journal.

[78]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[79]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[80]  H. Varmus,et al.  A Mouse Mammary Tumor Virus-Wnt-1 Transgene Induces Mammary Gland Hyperplasia and Tumorigenesis in Mice Lacking Estrogen Receptor-α , 1999 .

[81]  Z. Werb,et al.  Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. , 1999, Development.

[82]  M. Karkkainen,et al.  Overexpression of VEGF in Testis and Epididymis Causes Infertility in Transgenic Mice: Evidence for Nonendothelial Targets for VEGF , 1998, The Journal of cell biology.

[83]  F. Kittrell,et al.  A transgenic mouse model for mammary carcinogenesis , 1998, Oncogene.

[84]  L. Berlin,et al.  Standard of care. , 1998, AJR. American journal of roentgenology.

[85]  D. Troyer,et al.  A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis , 1998, Molecular and Cellular Biology.

[86]  E. McDermott,et al.  Hereditary breast cancer , 1997, The British journal of surgery.

[87]  A. Kaider,et al.  Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease‐free survival , 1997, International journal of cancer.

[88]  S. Hilsenbeck,et al.  Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. , 1997, Cancer research.

[89]  S. Hilsenbeck,et al.  Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53 , 1997, Molecular and cellular biology.

[90]  R. Ullrich,et al.  Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation. , 1996, Radiation research.

[91]  L. Amundadottir,et al.  Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. , 1996, Oncogene.

[92]  C. Liu,et al.  Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. , 1996, Genes & development.

[93]  J. Ward,et al.  p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. , 1996, Cancer research.

[94]  J. Rossant,et al.  The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse , 1996, Cell.

[95]  D. Gomez,et al.  Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. , 1996, Cancer research.

[96]  G. Peters,et al.  Cyclin D1 and prognosis in human breast cancer , 1996, International journal of cancer.

[97]  R. Cardiff,et al.  Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.

[98]  A. Graessmann,et al.  The SV40 T‐antigen induces premature apoptotic mammary gland involution during late pregnancy in transgenic mice , 1996, FEBS letters.

[99]  B. Koller,et al.  Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities , 1996, Nature Genetics.

[100]  A. Graessmann,et al.  SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals. , 1996, Oncogene.

[101]  K. McKenzie,et al.  Animal models for breast cancer. , 1995, Mutation research.

[102]  G. Stamp,et al.  Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. , 1995, Genes & development.

[103]  Junzhe Xu,et al.  The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues , 1995, Nature Genetics.

[104]  R. Palmiter,et al.  Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. , 1995, Cancer research.

[105]  S. Elledge,et al.  Cyclin D1 provides a link between development and oncogenesis in the retina and breast , 1995, Cell.

[106]  Satoshi Tanaka,et al.  Expression of whey acidic protein (WAP) genes in tissues other than the mammary gland in normal and transgenic mice expressing mWAP/hGH fusion gene , 1995, Molecular reproduction and development.

[107]  L. Amundadottir,et al.  Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[108]  D. Pinkel,et al.  Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. , 1995, Genes & development.

[109]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[110]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.

[111]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[112]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[113]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[114]  W. Muller,et al.  Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.

[115]  R. Palmiter,et al.  Distal regulatory elements from the mouse metallothionein locus stimulate gene expression in transgenic mice , 1993, Molecular and cellular biology.

[116]  J. A. Hamilton,et al.  Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.

[117]  A. Graessmann,et al.  Breast cancer formation in transgenic animals induced by the whey acidic protein SV40 T antigen (WAP-SV-T) hybrid gene. , 1993, Oncogene.

[118]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[119]  B. Hogan,et al.  Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. , 1992, The American journal of pathology.

[120]  J. Folkman,et al.  The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.

[121]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[122]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[123]  H. Varmus,et al.  Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice , 1992, Molecular and cellular biology.

[124]  G. Peters,et al.  Chromosome 11q13 abnormalities in human cancer. , 1991, Cancer cells.

[125]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice , 1990, Cell.

[126]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[127]  J. Moore,et al.  High levels of c-myc protein in human breast tumours determined by a sensitive ELISA technique. , 1989, Anticancer research.

[128]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[129]  T. Hoang,et al.  Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues , 1989, Molecular and cellular biology.

[130]  H. Varmus,et al.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice , 1988, Cell.

[131]  B. Groner,et al.  Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. , 1988, Genes & development.

[132]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[133]  B. Groner,et al.  Targeted c‐myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. , 1988, The EMBO journal.

[134]  D. Spandidos.  Oncogene activation in malignant transformation: a study of H-ras in human breast cancer. , 1987, Anticancer research.

[135]  P. Leder,et al.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.

[136]  B. Groner,et al.  Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[137]  R. Derynck,et al.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. , 1986, Science.

[138]  H. Abou-Issa,et al.  Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents. , 1985, Biochemical and biophysical research communications.

[139]  P. Leder,et al.  Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes , 1984, Cell.

[140]  P. Hand,et al.  Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[141]  I. Verma,et al.  Expression of cellular oncogenes in human malignancies. , 1984, Science.

[142]  J. Hassell,et al.  Polyoma viral middle T-antigen is required for transformation , 1982, Journal of virology.

[143]  R. Palmiter,et al.  Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs , 1981, Cell.

[144]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[145]  S. Pease,et al.  Advanced Protocols for Animal Transgenesis , 2011, Springer Protocols Handbooks.

[146]  W. Wurst,et al.  Generating conditional knockout mice. , 2011, Methods in molecular biology.

[147]  T. Saunders.  Inducible transgenic mouse models. , 2011, Methods in molecular biology.

[148]  K. Polyak,et al.  The mammary gland as an experimental model : a subject collection from Cold Spring Harbor perspectives in biology , 2011 .

[149]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[150]  G. Robinson,et al.  Cooperation of signalling pathways in embryonic mammary gland development , 2008, Nature Reviews Genetics.

[151]  R. Cardiff,et al.  Mouse mammary tumor biology: a short history. , 2007, Advances in cancer research.

[152]  Yan Geng,et al.  Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.

[153]  B. Asch.  Tumor viruses and endogenous retrotransposons in mammary tumorigenesis , 2005, Journal of mammary gland biology and neoplasia.

[154]  T. Mattfeldt,et al.  Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast , 2004, Virchows Archiv A.

[155]  R. Cardiff,et al.  The Comparative Pathology of Human and Mouse Mammary Glands , 2004, Journal of Mammary Gland Biology and Neoplasia.

[156]  L. Beex,et al.  Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study , 2004, Breast Cancer Research and Treatment.

[157]  B. Gusterson,et al.  Human Breast Development , 2004, Journal of Mammary Gland Biology and Neoplasia.

[158]  D. Barnes,et al.  Cyclin D1 in Breast Cancer , 2004, Breast Cancer Research and Treatment.

[159]  J. Voncken.  Genetic modification of the mouse. General technology; pronuclear and blastocyst injection. , 2003, Methods in molecular biology.

[160]  H. Varmus,et al.  A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. , 1999, Cancer research.

[161]  G. Casey.  The BRCA1 and BRCA2 breast cancer genes. , 1997, Current opinion in oncology.

[162]  P. Leder,et al.  Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice , 1997, Oncogene.

[163]  L. Hennighausen,et al.  Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53-independent pathways. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[164]  L. Hennighausen,et al.  Expression of a viral oncoprotein during mammary gland development alters cell fate and function: induction of p53-independent apoptosis is followed by impaired milk protein production in surviving cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[165]  A. Clark,et al.  Tissue-specific, temporally regulated expression mediated by the proximal ovine beta-lactoglobulin promoter in transgenic mice. , 1995, Cellular & molecular biology research.

[166]  R. Cardiff,et al.  Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. , 1994, Genes & development.

[167]  G. Peters,et al.  Chromosome 11q13 abnormalities in human breast cancer. , 1993, Cancer surveys.

[168]  T. Doetschman,et al.  Gene targeting in embryonic stem cells. , 1991, Biotechnology.

[169]  B. Hogan,et al.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. , 1990, Cell.